Shepherd Financial Partners LLC Takes $656,000 Position in Boston Scientific Corporation $BSX

Shepherd Financial Partners LLC bought a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to its most recent filing with the SEC. The fund bought 15,362 shares of the medical equipment provider’s stock, valued at approximately $656,000.

Other institutional investors also recently added to or reduced their stakes in the company. Kelleher Financial Advisors purchased a new stake in Boston Scientific during the second quarter worth about $25,000. FWL Investment Management LLC purchased a new position in Boston Scientific in the second quarter valued at about $26,000. Swiss RE Ltd. purchased a new position in Boston Scientific in the fourth quarter valued at about $26,000. Garton & Associates Financial Advisors LLC bought a new position in shares of Boston Scientific during the 4th quarter valued at approximately $26,000. Finally, Clal Insurance Enterprises Holdings Ltd bought a new position in shares of Boston Scientific during the 1st quarter valued at approximately $28,000. Institutional investors own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In related news, Director David C. Habiger acquired 2,100 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, with a total value of $99,939.00. Following the acquisition, the director owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This trade represents a 13.94% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Michael F. Mahoney bought 186,240 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was bought at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the purchase, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased 194,522 shares of company stock valued at $9,385,210 over the last three months. Company insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Zacks Research cut shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a report on Friday, June 5th. UBS Group reduced their price objective on Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Evercore set a $65.00 target price on Boston Scientific in a research note on Monday, July 6th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $65.00 price target on shares of Boston Scientific in a research report on Friday, June 12th. Twenty-four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific Stock Performance

Shares of BSX stock opened at $52.02 on Thursday. The firm’s 50 day moving average is $46.22 and its 200 day moving average is $58.22. The stock has a market capitalization of $75.39 billion, a P/E ratio of 21.06, a PEG ratio of 1.10 and a beta of 0.56. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $109.50. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same period in the previous year, the business earned $0.75 EPS. Boston Scientific’s revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, sell-side analysts anticipate that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its Board of Directors has initiated a share repurchase program on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.